Karenitecin (BNP1350)

DRUG3 trials

Sponsors

BioNumerik Pharmaceuticals, Inc.

Conditions

Brain NeoplasmsBrain TumorsCarcinomaCarcinoma, Non-Small-Cell LungMalignant Neoplasms, BrainMelanomaNeoplasm

Phase 1

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

CompletedNCT00097903

BioNumerik Pharmaceuticals, Inc.Carcinoma, Carcinoma, Non-Small-Cell Lung

Start: 2004-05-31End: 2013-05-31Updated: 2020-03-12

Phase 2

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

CompletedNCT00062478

BioNumerik Pharmaceuticals, Inc.Brain Neoplasms, Brain Tumors, Malignant Neoplasms, Brain

Start: 2001-10-31Updated: 2020-03-12

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

CompletedNCT00062491

BioNumerik Pharmaceuticals, Inc.Melanoma, Neoplasm

Start: 2002-05-31End: 2005-11-30Updated: 2020-03-12